Abstract
In order to have more specific tools available to approach amyloidogenesis in Alzheimers disease (AD), we have produced several polyclonal and monoclonal antibodies that recognize specific sequences of the amyloid β (Aβ) peptide. Here we present results that demonstrate that our monoclonal antibody EM5 recognizes an internal sequence (residues 11-16) of the Aβ peptide. This strategic localization of the epitope allowed us to employ this antibody, together with two previously reported polyclonal antibodies (EM2 and EM3, specific for AβX-40 and AβX- 42, respectively), in an immunohistochemical study aimed at exploring the differential distribution of longer (AβX- 40/42) and shorter (Aβ17-X) peptides along the various types of amyloid deposits of AD. This antibody panel was used in six AD brains, on sections from associative neocortex, striatum and cerebellar cortex. Single and double immunostaining revealed specific staining of vascular amyloid deposits and neuritic plaques by EM5 antibody, with high co-localization of EM2. Our results suggest that EM5 antibody recognizes pathogenic forms of Ab deposits (amyloid angiopathy and neuritic plaques) and reveals the existence of a subset of plaques with a profile similar to vascular deposits. Additionally, our results show that diffuse plaques in AD brains may contain Aβ17-X peptides as its principal component. EM5 may be a useful tool in research both on human and transgenic mice tissue that may aid in the study of molecular heterogeneity of plaques in AD.
Keywords: alzheimers disease, amyloid-b, immunohistochemistry, monoclonal antibody, neuritic plaques, amyloid angiopathy, mass spectrometry
Current Alzheimer Research
Title: Diversity of Senile Plaques in Alzheimers Disease as Revealed by a New Monoclonal Antibody that Recognizes an Internal Sequence of the Aβ Peptide
Volume: 2 Issue: 4
Author(s): Alberto Rabano, Adolfo Jimenez-Huete, Boris Acevedo, Miguel Calero, Jorge Ghiso, Israel Valdes, Jorge Gavilondo, Blas Frangione and Enrique Mendez
Affiliation:
Keywords: alzheimers disease, amyloid-b, immunohistochemistry, monoclonal antibody, neuritic plaques, amyloid angiopathy, mass spectrometry
Abstract: In order to have more specific tools available to approach amyloidogenesis in Alzheimers disease (AD), we have produced several polyclonal and monoclonal antibodies that recognize specific sequences of the amyloid β (Aβ) peptide. Here we present results that demonstrate that our monoclonal antibody EM5 recognizes an internal sequence (residues 11-16) of the Aβ peptide. This strategic localization of the epitope allowed us to employ this antibody, together with two previously reported polyclonal antibodies (EM2 and EM3, specific for AβX-40 and AβX- 42, respectively), in an immunohistochemical study aimed at exploring the differential distribution of longer (AβX- 40/42) and shorter (Aβ17-X) peptides along the various types of amyloid deposits of AD. This antibody panel was used in six AD brains, on sections from associative neocortex, striatum and cerebellar cortex. Single and double immunostaining revealed specific staining of vascular amyloid deposits and neuritic plaques by EM5 antibody, with high co-localization of EM2. Our results suggest that EM5 antibody recognizes pathogenic forms of Ab deposits (amyloid angiopathy and neuritic plaques) and reveals the existence of a subset of plaques with a profile similar to vascular deposits. Additionally, our results show that diffuse plaques in AD brains may contain Aβ17-X peptides as its principal component. EM5 may be a useful tool in research both on human and transgenic mice tissue that may aid in the study of molecular heterogeneity of plaques in AD.
Export Options
About this article
Cite this article as:
Rabano Alberto, Jimenez-Huete Adolfo, Acevedo Boris, Calero Miguel, Ghiso Jorge, Valdes Israel, Gavilondo Jorge, Frangione Blas and Mendez Enrique, Diversity of Senile Plaques in Alzheimers Disease as Revealed by a New Monoclonal Antibody that Recognizes an Internal Sequence of the Aβ Peptide, Current Alzheimer Research 2005; 2 (4) . https://dx.doi.org/10.2174/156720505774330500
DOI https://dx.doi.org/10.2174/156720505774330500 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Multi-Target Compounds Acting in the Central Nervous System Designed From Natural Products
Current Medicinal Chemistry Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Current Topics in Medicinal Chemistry Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry